{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/hypertension-in-pregnancy/management/pre-existing-hypertension-or-hypertension-before-20-weeks/","result":{"pageContext":{"chapter":{"id":"a7e6503b-bdb3-5f87-8485-0352a165acbf","slug":"pre-existing-hypertension-or-hypertension-before-20-weeks","fullItemName":"Scenario: Pre-existing hypertension, or hypertension before 20 weeks","depth":2,"htmlHeader":"<!-- begin field a335effc-aee6-456a-98d2-0e861dc6e9d6 --><h2>Scenario: Chronic hypertension, or new hypertension before 20 weeks' gestation</h2><!-- end field a335effc-aee6-456a-98d2-0e861dc6e9d6 -->","summary":"Covers the assessment and management of women with pre-existing chronic hypertension.","htmlStringContent":"<!-- begin item 17e9dbe3-9690-44e3-a24e-cf4c9d7424c7 --><!-- begin field 187711a4-c288-4b51-a8a1-acbc01598201 --><p>From age 13 years onwards (Female).</p><!-- end field 187711a4-c288-4b51-a8a1-acbc01598201 --><!-- end item 17e9dbe3-9690-44e3-a24e-cf4c9d7424c7 -->","topic":{"id":"6ecaddc4-ff30-5cf4-ad9e-1df6efa32f1b","topicId":"b42a4357-926e-40db-93be-eb2734585661","topicName":"Hypertension in pregnancy","slug":"hypertension-in-pregnancy","lastRevised":"Last revised in July 2020","chapters":[{"id":"be1a3062-ba16-5320-bc1f-7931438b3b5e","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"37d79826-12c0-54a5-859c-f5aab239dccb","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"7ede8737-53eb-57a2-9db3-c67e7b595b36","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"000e1ae9-fec8-5c7e-93fa-aac37cbed3b1","slug":"changes","fullItemName":"Changes"},{"id":"6aee7a8f-5861-5cdc-98a3-6cca34fc56c0","slug":"update","fullItemName":"Update"}]},{"id":"a142cb05-c8c8-5f0b-a31f-aee4193f794a","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"fb45ed4d-238b-5c83-a4c9-503c743ce614","slug":"goals","fullItemName":"Goals"},{"id":"9fe5bf45-a5b8-5910-9d8c-6c7d392f1779","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"152c0aed-a09e-585e-be86-456cff579be0","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"e424db7c-6f59-5395-8125-3f64c8335e1c","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"388966c0-e5d0-5421-b48f-b9c11780841e","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"aa780aa5-6dd7-53a0-893d-5f60840b81a9","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"c2bcbadf-68d8-5fa9-8752-b5b9846e022a","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"be8adaec-21d7-5658-acb7-9487648799b4","slug":"definition","fullItemName":"Definition"},{"id":"a31e2e01-f95d-55d6-a81d-9f251edbf121","slug":"prevalence","fullItemName":"Prevalence"},{"id":"fe25ef6b-b112-589a-aa03-6f59c10bb254","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"d1cacb2e-13ff-5c3f-9767-77524f5938ad","slug":"prognosis","fullItemName":"Prognosis"},{"id":"5a7a190a-9065-5e86-a995-19f480ddc1ae","slug":"complications","fullItemName":"Complications"},{"id":"39c857d6-2892-50eb-926a-0e42813dfdc8","slug":"long-term-health-implications","fullItemName":"Long-term health implications"}]},{"id":"76ba09af-ee47-5bcc-9270-4189dc2521ea","fullItemName":"Management","slug":"management","subChapters":[{"id":"29858bb6-e45a-5a43-bcf6-707da3b7f93e","slug":"pre-eclampsia","fullItemName":"Scenario: Pre-eclampsia"},{"id":"a7e6503b-bdb3-5f87-8485-0352a165acbf","slug":"pre-existing-hypertension-or-hypertension-before-20-weeks","fullItemName":"Scenario: Pre-existing hypertension, or hypertension before 20 weeks"},{"id":"525f57d9-c730-5acb-bc09-7a9500642f44","slug":"new-hypertension-after-20-weeks","fullItemName":"Scenario: New hypertension after 20 weeks"},{"id":"4fae554e-dd42-5116-9621-ba14519b2cc7","slug":"proteinuria-no-hypertension-after-20-weeks","fullItemName":"Scenario: Proteinuria and no hypertension after 20 weeks"},{"id":"189d666f-8d4d-5259-9194-b51f622a899e","slug":"postpartum-follow-up","fullItemName":"Scenario: Postpartum follow-up"}]},{"id":"df72f6fc-57f8-59ce-863e-0aafbe952576","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"d81aa3f7-0ac1-557e-aeb4-85c389e3d449","slug":"aspirin","fullItemName":"Aspirin"},{"id":"9c20faa9-01df-51f3-8ea5-1cff9dc7ba12","slug":"labetalol","fullItemName":"Labetalol"},{"id":"a8bfba7d-aa2a-58dd-8623-f94e9a11868e","slug":"methyldopa","fullItemName":"Methyldopa"},{"id":"80c4cdd6-918d-5b69-9052-a943de729d40","slug":"nifedipine","fullItemName":"Nifedipine"}]},{"id":"be2fc921-a370-593b-83f0-3adf0dbcb226","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"4e8e53ad-14b2-51b1-b527-d41b79469ddf","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"766ae496-9560-5803-92fa-8d7f71dc073e","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"0306f0ee-51ab-53f0-bfba-47ceda06c33c","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"204ea692-4044-51c2-b0d6-84f596e7ff27","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"fe018251-2fcc-5a91-9662-fd930649403a","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"961ee437-62d3-5138-83b6-d59d61ff6085","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"a96b6bfe-8e8a-51bd-beb4-c719aab1df08","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"76ba09af-ee47-5bcc-9270-4189dc2521ea","slug":"management","fullItemName":"Management"},"subChapters":[{"id":"dd93540b-f865-5c28-848b-1e0d6dba4223","slug":"management","fullItemName":"Management","depth":3,"htmlHeader":"<!-- begin field dc72dbfb-5235-439f-9963-9ce9f5a4dfa5 --><h3>How should I manage a woman with chronic hypertension?</h3><!-- end field dc72dbfb-5235-439f-9963-9ce9f5a4dfa5 -->","summary":null,"htmlStringContent":"<!-- begin item 2ea1a985-56de-4cd2-9304-250d4740b408 --><!-- begin field 1dc84852-c9de-4197-b3c8-9dabf795b541 --><ul><li><strong>Offer advice about:</strong><ul><li><strong>Healthy lifestyle</strong> (including work, rest, exercise, healthy diet, and weight) as recommended for all pregnant women. For more information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/antenatal-care-uncomplicated-pregnancy/\">Antenatal care - uncomplicated pregnancy</a>.</li><li><strong>Restriction of dietary salt. </strong>For more information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/hypertension-not-diabetic/\">Hypertension - not diabetic</a>.</li></ul></li><li><strong>Be aware that women with chronic hypertension are at high risk of </strong><strong><a class=\"topic-reference internal-reference\" href=\"/topics/hypertension-in-pregnancy/management/pre-eclampsia/#management\">pre-eclampsia</a> </strong><strong>and should be referred for consultant-led care at booking for specialist input to assess and manage the obstetric risk. </strong></li><li><strong>While the woman is waiting to see a specialist, if she is taking:</strong><ul><li><strong>An angiotensin-converting enzyme (ACE) inhibitor or angiotensin II receptor blocker (ARB) for hypertension</strong>, stop this immediately and prescribe an alternative antihypertensive if necessary:<ul><li>Explain that there is an increased risk of adverse fetal outcomes if these drugs are taken during pregnancy, particularly during the second and third trimesters.</li><li>Advise women who have continued to take ACE inhibitors during the first trimester that there is no strong evidence that this is associated with increased risk to the fetus.</li></ul></li><li><strong>An ACE inhibitor or ARB for another condition</strong> such as renal disease, treatment should also be stopped — seek specialist advice on alternative treatment.</li><li><strong>A thiazide or thiazide-like diuretic</strong> — prescribe an alternative antihypertensive if necessary or seek specialist advice on alternative treatment if being used for another indication.</li><li><strong>Any other antihypertensive</strong> — consider continuing existing treatment if necessary. Advise the woman that the limited evidence available has not shown an increased risk of congenital malformation with such treatments.</li></ul></li><li><strong>Be aware that pregnant women previously diagnosed with chronic hypertension may exhibit blood pressure within the normal range due to the physiological drop in blood pressure that occurs in early pregnancy. Continued antihypertensive treatment is <em>not</em> necessary if:</strong><ul><li>Sustained systolic blood pressure is less than 110 mmHg, <em><strong>or</strong></em></li><li>Sustained diastolic blood pressure is less than 70 mmHg, <em><strong>or</strong></em></li><li>The woman has symptomatic hypotension. </li></ul></li><li><strong>If an alternative antihypertensive treatment is required during pregnancy:</strong><ul><li>First-line treatment is usually labetalol if not contraindicated. </li><li>Consider nifedipine for women in whom labetalol is not suitable.</li><li>Consider methyldopa if both labetalol and nifedipine are not suitable.</li><li>Base the choice on any pre-existing treatment, side-effect profiles, risks (including fetal effects) and the woman's preference. <ul><li>For more information, including recommended doses, see the relevant sections in <a class=\"topic-reference internal-reference\" href=\"/topics/hypertension-in-pregnancy/prescribing-information/\">Prescribing information</a>.</li></ul></li></ul></li><li><strong>If a woman with chronic hypertension is <em>not </em>already taking antihypentensive treatment, while she is waiting to see a specialist, </strong><strong>offer drug treatment if there is:</strong><ul><li>Sustained systolic blood pressure of 140 mmHg or higher, <em><strong>or</strong></em></li><li>Sustained diastolic blood pressure of 90 mmHg or higher.</li></ul></li><li><strong>Target blood pressure following antihypertensive treatment in pregnancy is 135/85 mmHg.</strong></li><li><strong>Ensure that </strong><strong>aspirin 75—150 mg daily is prescribed from 12 weeks' gestation until birth.</strong><ul><li>This is usually arranged in secondary care, but should be initiated in primary care if the woman will not be seen by a specialist until after 12 weeks.<ul><li>Specialist advice should always be sought before prescribing aspirin to girls younger than 16 years of age, and in those with thrombophilia or uncontrolled blood pressure.</li></ul></li></ul></li><li><strong>Dipstick the urine for protein and measure blood pressure at each antenatal visit. </strong><ul><li>If dipstick screening is positive [1+ or more], use albumin:creatinine ratio or protein:creatinine ratio to quantify proteinuria in pregnant women.<ul><li>If using protein:creatinine ratio, use 30 mg/mmol as a threshold for significant proteinuria.</li><li>If using albumin:creatinine ratio, use 8 mg/mmol as a diagnostic threshold.</li><li>Do not use first morning urine void to quantify proteinuria in pregnant women.</li></ul></li></ul></li><li><strong>Assess for symptoms of </strong><strong><a class=\"topic-reference internal-reference\" href=\"/topics/hypertension-in-pregnancy/management/pre-eclampsia/#management\">pre-eclampsia</a> </strong><strong> at each antenatal visit. </strong>Advise the woman that she should seek immediate medical review if she develops any symptoms (including during the first four weeks postpartum).</li><li><strong>Arrange emergency secondary care assessment for any woman in whom <strong><a class=\"topic-reference internal-reference\" href=\"/topics/hypertension-in-pregnancy/management/pre-eclampsia/#management\">pre-eclampsia</a> </strong></strong><strong>is suspected.</strong></li></ul><!-- end field 1dc84852-c9de-4197-b3c8-9dabf795b541 --><!-- end item 2ea1a985-56de-4cd2-9304-250d4740b408 -->","subChapters":[{"id":"9c53662c-6a7c-5440-b480-c4d2495846ec","slug":"basis-for-recommendation-97b","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 33293725-bb6c-4bea-845d-9346f6e72f87 --><h4>Basis for recommendation</h4><!-- end field 33293725-bb6c-4bea-845d-9346f6e72f87 -->","summary":null,"htmlStringContent":"<!-- begin item 97bbd365-26f1-4d2e-97fb-9eeb7f163154 --><!-- begin field ff468b0a-37cc-43e0-8c08-f3c9c47eb9a3 --><p>The recommendations on management of pregnant women with pre-existing hypretension are largely based on expert opinion in the National Institute of Health and Care Excellence (NICE) guideline <em>Hypertension in pregnancy: diagnosis and management</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypertension-in-pregnancy/references/\">NICE, 2019b</a>].</p><h5>Early referral to obstetrics</h5><ul><li>In the absence of any explicit guidance from NICE, the recommendation to refer those at high risk of pre-eclampsia early in pregnancy is based on the Pre-eclampsia Community Guideline (PRECOG).<ul><li>The pre-eclampsia specialists in the guideline development group reviewed the available evidence and concluded that these women may benefit from specialist input to assess their obstetric risk [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypertension-in-pregnancy/references/\">PRECOG, 2004</a>]. An expert reviewer of this CKS topic also advised that it is routine practice for women who are at high risk of pre-eclampsia to be referred to a consultant obstetrician.</li></ul></li></ul><h5>Stopping angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs), and thiazide or thiazide-type diuretics</h5><ul><li>The recommendation to stop antihypertensive treatment with ACE inhibitors or ARBs during pregnancy is based on expert opinion in the National Institute of Health and Care Excellence (NICE) guideline <em>Hypertension in pregnancy: diagnosis and management</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypertension-in-pregnancy/references/\">NICE, 2019b</a>].<ul><li>Use of ACE inhibitors in the second and third trimesters is associated with oligohydramnios and its sequelae, including renal damage, hypoplastic lungs and bladder, compression of skull bones, and intrauterine growth restriction. There may also be increased risks of patent ductus arteriosus and premature delivery [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypertension-in-pregnancy/references/\">BUMPS, 2013</a>].</li><li>UKTIS states that there is no strong evidence that exposure to ACE inhibitors in the first trimester is associated with congenital malformations in the infant, but a lack of data means that the congenital malformation risk follwong exposure to ARBs cannot currently be quantified [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypertension-in-pregnancy/references/\">UKTIS, 2009</a>].</li></ul></li><li>NICE suggests that women taking ACE inhibitors or ARBs for other indications (such as renal disease) who are <em>planning</em> a pregnancy should discuss alternative treatment with the healthcare professional responsible for managing their condition <em>prior to conception</em>, but offers no advice on management of women with unplanned pregnancies while taking these drugs [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypertension-in-pregnancy/references/\">NICE, 2019b</a>]. The advice that primary care physicians should seek specialist advice on alternative treatment options for women taking ACE inhibitors or ARBs for indications other than hypertension is therefore pragmatic, based on what CKS considers to be good clinical practice.</li><li>NICE notes that that there may be an increased risk of infant congenital abnormalities and neonatal complications if thiazide or thiazide-type diuretics are taken during pregnancy and suggests that women taking these drugs who are <em>planning</em> a pregnancy should discuss alternative treatment with the healthcare professional responsible for managing their condition <em>prior to conception</em>. However, no advice on management of women with unplanned pregnancies while taking these drugs is offered [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypertension-in-pregnancy/references/\">NICE, 2019b</a>]. The advice that primary care physicians should switch to an alternative antihypertensive if appropriate, or seek specialist advice on alternative treatment options for women taking these medications for indications other than hypertension is therefore pragmatic, based on what CKS considers to be good clinical practice.</li></ul><h5>Antihypertensive treatment during pregnancy</h5><ul><li>NICE previously reviewed studies of antihypertensive drugs and found no obvious association with congenital abnormalities for methyldopa, labetalol, atenolol, metoprolol, oxprenolol, pindolol, prazosin, nifedipine, verapamil, bendroflumethiazide, furosemide, and hydralazine. No or very little information about other antihypertensive drugs is available [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypertension-in-pregnancy/references/\">National Collaborating Centre for Women's and Children's Health, 2010</a>].</li><li>The UK Teratology Information Service (UKTIS) has also carried out systematic evidence reviews of the pregnancy safety of beta-blockers, calcium channel blockers, and methyldopa, with no robust evidence of adverse fetal outcomes noted [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypertension-in-pregnancy/references/\">UKTIS, 2019</a>].</li></ul><!-- end field ff468b0a-37cc-43e0-8c08-f3c9c47eb9a3 --><!-- end item 97bbd365-26f1-4d2e-97fb-9eeb7f163154 -->","subChapters":[]}]}]}}},"staticQueryHashes":["3666801979"]}